Asset / Drug

HYMPAVZI

Drug and asset intelligence for HYMPAVZI with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Pfizer →

Recent signals(2)

RegulatoryJune 16, 2026

European Commission Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment

The European Commission has approved HYMPAVZI for treating hemophilia A or B in patients 12 years and older with inhibitors, based on Phase 3 data showing significant bleed reduction.

RegulatoryJune 10, 2026

FDA Approves Pfizer’s HYMPAVZI for Expanded Hemophilia A and B Indications

The FDA has approved an expanded indication for Pfizer’s HYMPAVZI to treat hemophilia A or B in patients aged 6 and older, including those with inhibitors.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Pfizer — HYMPAVZI

Monitor the FDA's upcoming decision on the supplemental Biologics License Application for HYMPAVZI, expected in Q2 2026, and any competitive responses from other hemophilia therapies.

June 16, 2026 · N/A

Topline Data

Pfizer — HYMPAVZI

Monitor uptake rates of HYMPAVZI in the pediatric population and any competitive responses from other hemophilia treatments.

June 10, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

B →

Hematology →

Hematology · Hemophilia A/B →

Hemophilia A →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.